MB49 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide MB49-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

MB49

Mouse

MB49 cells are derived from C57BL/Icrf-a' mouse bladder epithelial cells that were transformed by a single 24-hour treatment with the chemical carcinogen 7, 12-dimethylbenz[a]anthracene (DMBA) on the second day of a long term primary culture. Transformed cells transplanted into syngeneic mice were shown to generate carcinomas. While of male origin, karyotype analyses indicate the loss of the Y chromosome in 100% of the cells analyzed. This abnormality is a frequent early event in human bladder cancer.

Bladder Cancer

Oncology

In Vivo Anti-Tumor Efficacy Assay

MB49-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays